PUBLICATIONS

Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden inpatients with triple negative breast cancer and residual tumor

Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden inpatients with triple negative breast cancer and residual tumor

Circulating tumor DNA (ctDNA), a plasma-based biomarker, reveals real-time data about disease/treatment progression. We have previously shown that ctDNA detection after NAC and prior to surgery signals poor prognosis in TNBC patients using an academic hospital-based tumor bespoke assay. To validate and extend these results, we performed ctDNA measurements at 4 time points in non-pCR TNBC patients participating in our TRICIA study (NCT04874064).

read more
The Prognostic Value of Circulating Tumor DNA in Triple Negative Breast Cancer Patients with Incomplete Response to Neoadjuvant Chemotherapy

The Prognostic Value of Circulating Tumor DNA in Triple Negative Breast Cancer Patients with Incomplete Response to Neoadjuvant Chemotherapy

The most aggressive form of breast cancer is triple negative breast cancer (TNBC), so called because these tumors do not express estrogen, progesterone, or HER2 receptors. About half of TNBCs treated with neoadjuvant chemotherapy (NAC) will have a residual tumor at surgery (non-pathological complete response or non-pCR), signaling chemoresistance and poor prognosis. Further adjuvant chemotherapy (Xeloda) results in improved survival in about 15% of non-pCR patients. Circulating tumor DNA (ctDNA), a plasma-based biomarker, reveals real-time data about disease/treatment progression.

read more
IARC Nov 8-10 conference 2022

IARC Nov 8-10 conference 2022

Exactis’ PMT registry offers invaluable insights into disease impacts, disparities, and treatment patterns. PMT, a standardized digital cancer registry, spans 16 hospitals across 5 Canadian provinces. This comprehensive data, inclusive of demographics, diagnosis, treatments, and biomarkers, underscores the registry’s potential to enhance our understanding of oncological trends in Canada, ensuring more accurate evaluations of clinical benefits and treatment gaps in the real-world setting.

read more